This is further confounded by discordant ER, PR, and HER2 + status between multiple samples from a patient attributed to reasons including a change in cancer biology between sample sites and timepoints, sampling error, and accuracy and reproducibility of the receptor assays [10]. This evidence concerns the gene ERBB2 and cancer.